Clinical EfficacyBarzolvolimab showed a 97% complete response rate for at least one time point and 100% overall response rate using a single dose in ColdU and SD.
Financial StrengthThe company ended the quarter financially strong with $802.3 million in cash, which management believes provides runway through 2027.
Pipeline DevelopmentThe unique mast-cell-depleting mechanism of barzolvolimab offers a differentiated, best-in-class profile that stands to unlock significant commercial potential in urticarias and other mast cell-driven diseases.